期刊文献+

血管内皮生长因子、微血管密度及Ki-67在宫颈鳞癌中的表达及意义 被引量:1

Significance and expression of vascular endothelial growth factor,microvessel density and Ki-67 in human squamous-cell carcinoma of cervix
原文传递
导出
摘要 目的探讨血管内皮生长因子(VEGF)、微血管密度(MVD)及Ki-67在宫颈鳞状细胞癌中的表达及意义。方法采用免疫组织化学S-P法测定45例宫颈鳞癌组织和10例正常宫颈组织中VEGF、Ki-67和F8的表达。结果宫颈鳞癌中VEGF的表达阳性率为77.78%,Ki-67标记指数(Ki-67LI)和MVD分别为12.7±4.1和37±10,VEGF表达水平与肿瘤恶性程度、Ki-67 LI和MVD计数呈正相关。结论VEGF有促进肿瘤细胞增殖及血管生成的作用,联合检测VEGF、Ki-67和F8可作为病理诊断的补充,对患者预后判断和治疗方案的选择有重要的参考价值。 Objective To investigate the significance and expression of vascular endothelial growth factor( VEGF), microvessel density (MVD) and Ki - 67 in human squamous - cell carcinoma of cervix. Methods Expression of VEGF, Ki - 67 and F8 were detected by immunohistochemical S - P technique in cervical tissues of 45 cases of cervical squamous - cell carcinomas and 10 cases of normal cervical tissues. Results The positive rate of VEGF was 77.78%, Ki - 67 labeling index ( Ki - 67LI) and MVD were 12.7 ± 4. 1 and 37 ± 10 respectively . The expression of VEGF correlated positively with the grade of cervical squamous - cell carcinoma, Ki - 67LI and MVD. Conclusion VEGF plays a role in cancer cell proliferation and tumor anglogenesis. Evaluating of VEGF, Ki- 67 and F8 is the supplement of pathological diagnosis, which is important to evaluate the patient' s prognosis and select suitable therapy.
出处 《临床医学》 CAS 2007年第3期89-90,共2页 Clinical Medicine
关键词 宫颈鳞癌 血管内皮生长因子 微血管密度计数 细胞增殖 免疫组织化学 Human squamous -cell carcinoma of cervix Vascular endothelial growth factor Microvessel density Cell proliferation Immunohistochemistry
  • 相关文献

参考文献8

二级参考文献21

  • 1鲁祥和.人星形细胞瘤血管内皮生长因子表达[J].临床肿瘤学杂志,1998,3(4):13-15. 被引量:1
  • 2Ohbu M,Kobayashi N,Okayasu I.Expression of cell cycle regulatory proteins in the multistep process of oesophageal carcinogenesis:stepwise over-expression of cyclin E and P53,reduction of p21waf/cipl and dysregulation of cyclin D1 and P27kip1.Histopathology,2001,39:589-596.
  • 3Sedlacek TV.Advances in the diagnosis and treatment of human papillomavirus infections.Clin Obstet Gynecol,1999,42:206-220.
  • 4Wolf JK,Ramirez PT.The molecular biology of cervical cancer.Cancer Invest,2001,19:621-629.
  • 5Veldman T,Horikawa I,Barrett JC,et al.Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6oncoprotein.J Virol,2001,75:4467-4472.
  • 6Oh ST,Kyo S,Laimins LA.Telomerase activation by human papillomavirus type 16 E6 protein:induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites.J Virol,2001,75:5559-5566.
  • 7Frost M,Bobak JB,Gianani R,et al.Localization of telomerase hTERT protein and hTR in benign mucosa,dysplasia and squamous cell carcinoma of cervix.Am J Clin Pathol,2000,114:726-734.
  • 8El-Ddeiry WS.P21/53,cellular growth control and genomic integrity.Curr Top Microbiol Immunol,1998,227:121-137.
  • 9Bourden JC,Deguin CD,Lelong JC,et al.Further characterization of the P53 responsive element identication of new candidate gene for trans-activation by P53.Oncogene,1997,14:85-94.
  • 10Follen M,Schottenfeld D.Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials.Cancer,2001,91:1758-1771.

共引文献14

同被引文献5

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部